What Should Researchers Do When a Participant Withdraws?

Participant withdrawal is an inevitable reality in clinical research. Whether conducting a pharmaceutical trial, dietary supplement study, or behavioral intervention research, investigators must be prepared to handle withdrawals appropriately. The right to withdraw from a study at any time, without penalty or loss of benefits, is a fundamental ethical principle in human subjects research—but managing that withdrawal properly requires careful attention to regulatory requirements, documentation standards, and participant rights.

Understanding how to handle participant withdrawals is not just about compliance; it's about upholding the ethical foundation of clinical research and maintaining study integrity. This comprehensive guide will walk you through the essential steps researchers should take when a participant chooses to withdraw.

Understanding the Right to Withdraw

Before diving into procedures, it's critical to understand that participant withdrawal is an absolute right, not a privilege. During the informed consent process, participants must be informed that they can discontinue their participation at any time without providing a reason and without facing any negative consequences.

This right is foundational to ethical research and is emphasized in:

Researchers who fail to honor withdrawal requests or who pressure participants to continue violate fundamental ethical principles and regulatory requirements. As part of training requirements for research investigators and study staff, all team members should understand these participant rights thoroughly.

Types of Withdrawal in Clinical Research

Not all withdrawals are the same. Understanding the different types helps determine the appropriate response:

Complete Withdrawal

The participant wishes to stop all study activities and does not want any further contact from the research team. In this scenario, investigators should:

  • Respect the participant's wishes completely
  • Cease all study-related procedures immediately
  • Document the withdrawal thoroughly
  • Not attempt further contact unless the participant specifically consents

Partial Withdrawal

The participant may wish to discontinue certain study procedures (such as the investigational intervention) but agrees to continue with follow-up assessments or data collection. This requires careful documentation of:

  • Which specific procedures the participant is withdrawing from
  • Which procedures they consent to continue
  • The date and scope of the partial withdrawal

Withdrawal of Consent for Future Use of Data

Some participants may request that their previously collected data not be used in study analyses. This creates complex considerations:

  • Data already analyzed and included in publications generally cannot be "unanalyzed"
  • Future use of identifiable data should cease
  • The protocol should specify how such requests will be handled
  • IRB guidance should be sought for complex situations

Immediate Steps When a Participant Withdraws

1. Document the Withdrawal Request

The moment a participant expresses their intention to withdraw, documentation should begin:

  • Date and time of the withdrawal request
  • Method of communication (in-person, phone, email, text message)
  • Person who received the withdrawal request
  • Participant's stated reason for withdrawal (if provided voluntarily)
  • Type of withdrawal (complete, partial, or data-specific)

Important: Never pressure participants to provide a reason for withdrawal. If they volunteer information, document it accurately, but make clear that providing a reason is optional.

2. Clarify the Scope of Withdrawal

Have a respectful conversation to understand:

  • Does the participant want to stop all study activities?
  • Are they willing to complete any final safety assessments?
  • Do they consent to be contacted for follow-up on safety concerns?
  • Can previously collected data be used in analyses?
  • Should future contact be avoided entirely?

Use clear, non-technical language and avoid any suggestion that the participant should reconsider. This conversation should be documented thoroughly.

3. Stop All Study Procedures Immediately

Once withdrawal is confirmed:

  • Discontinue the investigational product or intervention
  • Cancel all scheduled study visits
  • Inform all study team members of the withdrawal
  • Update study databases and scheduling systems
  • Ensure the participant is not contacted for study-related activities (unless they've consented to specific follow-up)

4. Address Immediate Safety Concerns

Even when a participant withdraws, investigators retain safety responsibilities:

  • Assess whether discontinuing the intervention poses immediate safety risks
  • Provide appropriate medical guidance for discontinuation (e.g., tapering protocols for certain medications)
  • Offer referrals to alternative care if appropriate
  • Document safety recommendations provided to the participant

Participants cannot be compelled to follow safety recommendations, but investigators must offer them and document that they were provided.

Required Documentation and Reporting

Internal Study Documentation

Proper recordkeeping is essential. As outlined in guidance on research recordkeeping after IRB approval, withdrawal documentation should include:

  • Withdrawal form or note: Signed when possible, or documented contemporaneously if the participant declines to sign
  • Source documentation: Notes from conversations about the withdrawal
  • Case report form updates: Marking the participant as withdrawn with the appropriate date and reason code
  • Study file updates: Ensuring the master enrollment log reflects the withdrawal

IRB Reporting Requirements

Withdrawals typically do not require immediate IRB reporting as adverse events, but they should be:

  • Summarized in continuing review reports: IRBs need to know withdrawal rates and reasons to assess study risk-benefit ratios
  • Reported promptly if indicating a problem: Multiple withdrawals for the same concerning reason (such as participant complaints about study procedures or unexpected side effects) may require immediate reporting
  • Included in protocol amendments: If withdrawal rates are unexpectedly high, protocol modifications may be needed

Sponsor Reporting

For industry-sponsored trials:

  • Follow sponsor-specific reporting timelines for withdrawals
  • Provide required data elements (often including reason codes)
  • Report safety concerns that emerge during withdrawal visits
  • Maintain communication about enrollment impacts

Analyzing and Using Data from Withdrawn Participants

The use of data collected before withdrawal requires careful consideration:

Intent-to-Treat Analysis

In most clinical trials, data collected before withdrawal should be included in intent-to-treat analyses unless the participant specifically withdraws consent for data use. This principle:

  • Preserves the integrity of randomization
  • Provides a realistic estimate of treatment effects
  • Reduces bias from differential withdrawal

Respect for Participant Wishes

If a participant explicitly requests that their data not be used:

  • Honor this request for future analyses when feasible
  • Understand that data already in published reports cannot be retracted
  • Document the request clearly
  • Consult with your IRB about complex situations

Protocol-Specified Procedures

Your research protocol should specify in advance:

  • How data from withdrawn participants will be handled
  • Whether participants will be asked about data use preferences during withdrawal
  • Analysis populations and how withdrawals affect them

These specifications should be reviewed during IRB submission to ensure they align with ethical standards.

Common Withdrawal Scenarios and How to Handle Them

Scenario 1: Participant Withdraws Due to Adverse Events

Response: - Thoroughly document the adverse event - Provide appropriate medical care or referrals - Follow protocol-specified procedures for safety follow-up - Report to the IRB and sponsor according to adverse event reporting requirements - Consider whether the event indicates increased risk requiring protocol modification

Scenario 2: Participant Relocates or Becomes Unreachable

Response: - Document attempts to contact the participant - Distinguish between voluntary withdrawal and loss to follow-up - Follow protocol procedures for lost-to-follow-up participants - Consider whether withdrawal due to study burden indicates a broader problem

Scenario 3: Investigator-Initiated Withdrawal

Response: - Ensure there is a valid protocol-specified reason (safety concerns, protocol non-compliance) - Document the rationale thoroughly - Communicate clearly with the participant about the reason - Ensure the decision is not punitive or discriminatory - Report to the IRB if required by protocol or if raising ethical concerns

Scenario 4: Participant Withdraws from Intervention but Agrees to Follow-Up

Response: - Obtain clear documentation of what the participant will and won't continue - Revise the participant's study schedule accordingly - Ensure all study team members understand the new parameters - Continue to protect participant rights and confidentiality for ongoing activities

Special Considerations for Vulnerable Populations

Research with Children

When conducting research with children:

  • Both the child's dissent and parental withdrawal must be honored
  • Age-appropriate explanations should be provided
  • Special sensitivity is needed to ensure children are not pressured

International Research

For multi-national studies:

  • Cultural considerations may affect how withdrawal is communicated
  • Translation of withdrawal documentation may be necessary
  • Local regulations may impose additional requirements

Preventing Unnecessary Withdrawals

While respecting the right to withdraw is paramount, researchers can take steps to minimize unnecessary withdrawals:

During Study Design

  • Design protocols with realistic participant burden in mind
  • Consider decentralized or hybrid models to reduce travel requirements
  • Build in flexibility where scientifically appropriate

During Informed Consent

  • Provide realistic expectations about study procedures and time commitment
  • Ensure participants understand what's involved before enrolling
  • Use clear, accessible consent language

During Study Conduct

  • Maintain excellent communication with participants
  • Address concerns promptly before they escalate to withdrawal
  • Provide appropriate compensation for time and travel
  • Create a respectful, welcoming environment for study visits

When to Modify Your Protocol

High withdrawal rates may signal problems requiring protocol modifications:

  • Withdrawal rate exceeds 20%: Generally warrants investigation
  • Participants cite similar reasons: Indicates systematic issues
  • Withdrawals cluster at specific timepoints: May indicate excessive burden at those visits

If protocol modifications are needed, follow protocol amendment IRB requirements to implement changes appropriately.

Best Practices for Managing Withdrawals

  1. Develop standard operating procedures: Create clear, written procedures for handling withdrawals that all study team members follow
  1. Train your team thoroughly: Ensure everyone understands participant rights and documentation requirements
  1. Use standardized forms: Create withdrawal forms that capture all necessary information consistently
  1. Maintain respectful communication: Always treat participants with dignity, especially during withdrawal
  1. Track and analyze withdrawal data: Regular review of withdrawal rates and reasons can identify problems early
  1. Document everything: When in doubt, document more rather than less
  1. Consult when uncertain: Reach out to your IRB, sponsor, or regulatory experts when facing unusual situations
  1. Follow up on safety: Even after withdrawal, investigators have ethical obligations to ensure participant safety

Conclusion

Managing participant withdrawals is a fundamental responsibility of clinical research that requires balancing regulatory compliance, ethical obligations, and scientific integrity. By understanding the different types of withdrawal, following proper documentation procedures, respecting participant wishes, and learning from withdrawal patterns, researchers can uphold the rights of research participants while maintaining study quality.

Remember that how you handle withdrawals reflects your commitment to ethical research conduct and can impact your reputation with participants, sponsors, and regulatory bodies. When participants are treated with respect throughout their research experience—including when they choose to withdraw—it strengthens the entire research enterprise.

Need Expert IRB Support for Your Research?

At Elemental IRB, we understand the complexities of managing clinical research, from initial submission through study completion. Our experienced team provides responsive, expert guidance on all aspects of IRB compliance, including proper handling of participant withdrawals, protocol amendments, and adverse event reporting.

Whether you're conducting pharmaceutical trials, supplement studies, medical device research, or behavioral interventions, we offer streamlined IRB review with transparent pricing and exceptional customer service. Contact Elemental IRB today to learn how we can support your research with efficient, ethical oversight that keeps your study on track.